Smartlab Europe

Drug Research

Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States

Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec® ODT in the U.S., and is indicated for the acute...

Phillips-Medisize and Exact Sciences Collaborate to Fight Colorectal Cancer

Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic and MedTech devices, announces the successful collaboration with Exact Sciences, a global leader in cancer diagnostics, to advance early cancer detection. Fueled by a relentless pursuit for smarter, earlier...

Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery

Standigm Inc., the leading workflow artificial intelligence (AI) drug discovery company, announced that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd, a life science and green chemicals company. Standigm has dramatically improved...

IFF Displays Innovative Pharmaceutical Solutions, Tailored to Address Current, Future Industry Challenges

As the pharmaceutical industry continues to evolve – introducing increasingly complex drugs, unique applications and new dosage forms – the Pharma Solutions division of IFF is dedicated to helping formulators and manufacturers evolve alongside it. Armed with extensive expertise...

Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation gene editing tools, announced that the two companies have entered into a strategic research...

University of Kent research identifies novel Covid-19 therapy

Researchers have identified a potential new treatment that suppresses the replication of SARS-CoV-2, the coronavirus that causes Covid-19. In order to multiply, all viruses, including coronaviruses, infect cells and reprogramme them to produce novel viruses. The research revealed that cells...

Pfizer and BioNTech Receive First U.S. FDA EUA of a COVID-19 Vaccine in Children Ages 5 Through 11 Years

Pfizer Inc. and BioNTech SE announced that the U.S. FDA has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as 5 to <12 years). For this age group,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »